



Supplementary figure 1




Supplementary figure 2



Supplementary figure 3


A

IPI- α V β 6.2




B

IPI- α V β 8.1




C

IPI- α V β 8.8





Supplementary figure 4

IPI- $\alpha 5\beta 1.2$




IPI- $\alpha 5\beta 1.4$








- $\alpha V\beta 1$ (EC50 = 157 ± 29 nM)
- $\alpha V\beta 3$ (EC50 = 4.4 ± 0.4 nM, Kd = 4.6 ± 0.4 nM)
- $\alpha V\beta 5$ (EC50 = 8.5 ± 1.5 nM, Kd = 5.2 ± 1.9 nM)
- $\alpha 5\beta 1$ (EC50 = 55 ± 6 nM, Kd = 49 ± 7 nM)
- $\alpha 8\beta 1$ (EC50 = 2311 ± 36 nM)
- $\alpha IIb\beta 3$ (EC50 not well fit)




- $\alpha V\beta 6$ (EC50 = 3.1 ± 0.3 nM)
- $\alpha V\beta 8$ (EC50 = 14.7 ± 1.5 nM, Kd = 12.5 ± 2.2 nM)

Supplementary figure 6





Supplementary figure 8



Supplemental Table 1. K_D and kinetic rates of IPI integrin antibodies.				
		k_{on} (10^4 M $^{-1}$ s $^{-1}$)	k_{off} (10^{-4} s $^{-1}$)	K_d (nM)
$\alpha V\beta 1$ ectodomain	IPI- $\alpha V\beta 3.7$	-	-	-
	IPI- $\alpha V\beta 3.13$	-	-	-
	IPI- $\alpha V\beta 5.9$	-	-	-
	IPI- $\alpha V\beta 6.2$	N.R.F.	N.R.F.	N.R.F.
	IPI- $\alpha V\beta 6.3$	-	-	-
	IPI- $\alpha V\beta 6.4$	-	-	-
	IPI- $\alpha V\beta 6.12$	N.R.F.	N.R.F.	N.R.F.
	IPI- $\alpha V\beta 8.1$	-	-	-
	IPI- $\alpha V\beta 8.8$	-	-	-
	IPI- $\alpha 5\beta 1.2$	-	-	-
IPI- $\alpha 5\beta 1.4$	-	-	-	
$\alpha V\beta 3$ ectodomain	IPI- $\alpha V\beta 3.7$	25.6 \pm 2.0	0.98 \pm 0.16	0.39 \pm 0.08
	IPI- $\alpha V\beta 3.13$	19.9 \pm 0.9	2.3 \pm 0.2	1.2 \pm 0.1
	IPI- $\alpha V\beta 5.9$	1.4 \pm 0.1	69.8 \pm 2.1	490.5 \pm 17.2
	IPI- $\alpha V\beta 6.2$	-	-	-
	IPI- $\alpha V\beta 6.3$	-	-	-
	IPI- $\alpha V\beta 6.4$	-	-	-
	IPI- $\alpha V\beta 6.12$	-	-	-
	IPI- $\alpha V\beta 8.1$	-	-	-
	IPI- $\alpha V\beta 8.8$	-	-	-
	IPI- $\alpha 5\beta 1.2$	-	-	-
IPI- $\alpha 5\beta 1.4$	-	-	-	
$\alpha V\beta 5$ ectodomain	IPI- $\alpha V\beta 3.7$	-	-	-
	IPI- $\alpha V\beta 3.13$	-	-	-
	IPI- $\alpha V\beta 5.9$	14.9 \pm 0.5	7.2 \pm 0.5	4.8 \pm 0.4
	IPI- $\alpha V\beta 6.2$	-	-	-
	IPI- $\alpha V\beta 6.3$	-	-	-
	IPI- $\alpha V\beta 6.4$	-	-	-
	IPI- $\alpha V\beta 6.12$	-	-	-
	IPI- $\alpha V\beta 8.1$	-	-	-
	IPI- $\alpha V\beta 8.8$	-	-	-
	IPI- $\alpha 5\beta 1.2$	-	-	-
IPI- $\alpha 5\beta 1.4$	-	-	-	
$\alpha V\beta 6$ ectodomain	IPI- $\alpha V\beta 3.7$	-	-	-
	IPI- $\alpha V\beta 3.13$	-	-	-
	IPI- $\alpha V\beta 5.9$	-	-	-
	IPI- $\alpha V\beta 6.2$	13.5 \pm 0.2	15.2 \pm 2.2	11.3 \pm 0.5
	IPI- $\alpha V\beta 6.3$	4.9 \pm 0.3	1.1 \pm 0.3	2.3 \pm 0.6
	IPI- $\alpha V\beta 6.4$	7.4 \pm 2.0	7.1 \pm 1.7	10.4 \pm 4.7
	IPI- $\alpha V\beta 6.12$	47.4 \pm 4.6	10.4 \pm 1.8	2.2 \pm 0.2
	IPI- $\alpha V\beta 8.1$	-	-	-
	IPI- $\alpha V\beta 8.8$	-	-	-
	IPI- $\alpha 5\beta 1.2$	-	-	-
IPI- $\alpha 5\beta 1.4$	N.R.F.	N.R.F.	N.R.F.	

Supplemental Table 1, cont. K_D and kinetic rates of IPI integrin antibodies				
		k _{on} (10 ⁴ M ⁻¹ s ⁻¹)	k _{off} (10 ⁻⁴ s ⁻¹)	K _d (nM)
αVβ8 ectodomain	IPI-αVβ3.7	-	-	-
	IPI-αVβ3.13	-	-	-
	IPI-αVβ5.9	-	-	-
	IPI-αVβ6.2	2.4 ± 0.4	40.7 ± 1.9	172.0 ± 35.9
	IPI-αVβ6.3	-	-	-
	IPI-αVβ6.4	1.3 ± 0.7	1.9 ± 1.4	18.9 ± 7.1
	IPI-αVβ6.12	1.1 ± 0.2	44.7 ± 12.6	386.9 ± 34.6
	IPI-αVβ8.1	17.6 ± 2.2	0.45 ± 0.23	0.27 ± 0.16
	IPI-αVβ8.8	10.2 ± 6.8	1.6 ± 1.2	1.6 ± 0.7
	IPI-α5β1.2	-	-	-
IPI-α5β1.4	-	-	-	
α5β1 ectodomain	IPI-αVβ3.7	-	-	-
	IPI-αVβ3.13	-	-	-
	IPI-αVβ5.9	-	-	-
	IPI-αVβ6.2	-	-	-
	IPI-αVβ6.3	-	-	-
	IPI-αVβ6.4	-	-	-
	IPI-αVβ6.12	-	-	-
	IPI-αVβ8.1	-	-	-
	IPI-αVβ8.8	-	-	-
	IPI-α5β1.2	28.0 ± 3.2	5.3 ± 0.6	1.9 ± 0.2
IPI-α5β1.4	19.6 ± 0.8	8.4 ± 0.8	4.3 ± 0.1	
α8β1 ectodomain	IPI-αVβ3.7	-	-	-
	IPI-αVβ3.13	-	-	-
	IPI-αVβ5.9	-	-	-
	IPI-αVβ6.2	-	-	-
	IPI-αVβ6.3	-	-	-
	IPI-αVβ6.4	-	-	-
	IPI-αVβ6.12	-	-	-
	IPI-αVβ8.1	-	-	-
	IPI-αVβ8.8	-	-	-
	IPI-α5β1.2	-	-	-
IPI-α5β1.4	-	-	-	
αIIbβ3 ectodomain	IPI-αVβ3.7	-	-	-
	IPI-αVβ3.13	-	-	-
	IPI-αVβ5.9	-	-	-
	IPI-αVβ6.2	-	-	-
	IPI-αVβ6.3	-	-	-
	IPI-αVβ6.4	-	-	-
	IPI-αVβ6.12	-	-	-
	IPI-αVβ8.1	-	-	-
	IPI-αVβ8.8	-	-	-
	IPI-α5β1.2	-	-	-
IPI-α5β1.4	-	-	-	

Gray cells represent antibody that bind to the targeting antigen.

-: non-significant binding; R₀ (Response units at the end of association phase) was less than 10% of the R₀ of specific antibodies on the same target antigen.

N.R.F.: No reliable fit. The R₀ was between 10% and 20% of the R₀ of specific antibodies on the same target antigen, but a fit with 3 or more concentrations of the antibody with an R square > 0.9 could not be obtained (Supplementary Figures 1-4).